IMPORTANCE: Typical cognitive aging may be defined as age-associated changes in cognitive performance in individuals who remain free of dementia. Ideally, the full adult age spectrum should be included to assess brain imaging findings associated with typical aging. OBJECTIVE: To compare age, sex, and APOE ε4 effects on memory, brain structure (adjusted hippocampal volume [HVa]), and amyloid positron emission tomography (PET) in cognitively normal individuals aged 30 to 95 years old. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional observational study (March 2006 to October 2014) at an academic medical center. We studied 1246 cognitively normal individuals, including 1209 participants aged 50 to 95 years old enrolled in a population-based study of cognitive aging and 37 self-selected volunteers aged 30 to 49 years old. MAIN OUTCOMES AND MEASURES: Memory, HVa, and amyloid PET. RESULTS: Overall, memory worsened from age 30 years through the 90s. The HVa worsened gradually from age 30 years to the mid-60s and more steeply beyond that age. The median amyloid PET was low until age 70 years and increased thereafter. Memory was worse in men than in women overall (P < .001) and more specifically beyond age 40 years. The HVa was lower in men than in women overall (P < .001) and more specifically beyond age 60 years. There was no sex difference in amyloid PET at any age. Within each sex, memory performance and HVa were not different by APOE ε4 status at any age. From age 70 years onward, APOE ε4 carriers had significantly greater median amyloid PET than noncarriers. However, the ages at which 10% of the population were amyloid PET positive were 57 years for APOE ε4 carriers and 64 years for noncarriers. CONCLUSIONS AND RELEVANCE: Male sex is associated with worse memory and HVa among cognitively normal individuals, while APOE ε4 is not. In contrast, APOE ε4 is associated with greater amyloid PET (from age 70 years onward), while sex is not. Worsening memory and HVa occur at earlier ages than abnormal amyloid PET. Therefore, neuropathological processes other than β-amyloidosis must underlie declines in brain structure and memory function in middle age. Our findings are consistent with a model of late-onset Alzheimer disease in which β-amyloidosis arises in later life on a background of preexisting structural and cognitive decline that is associated with aging and not with β-amyloid deposits.
IMPORTANCE: Typical cognitive aging may be defined as age-associated changes in cognitive performance in individuals who remain free of dementia. Ideally, the full adult age spectrum should be included to assess brain imaging findings associated with typical aging. OBJECTIVE: To compare age, sex, and APOE ε4 effects on memory, brain structure (adjusted hippocampal volume [HVa]), and amyloid positron emission tomography (PET) in cognitively normal individuals aged 30 to 95 years old. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional observational study (March 2006 to October 2014) at an academic medical center. We studied 1246 cognitively normal individuals, including 1209 participants aged 50 to 95 years old enrolled in a population-based study of cognitive aging and 37 self-selected volunteers aged 30 to 49 years old. MAIN OUTCOMES AND MEASURES: Memory, HVa, and amyloid PET. RESULTS: Overall, memory worsened from age 30 years through the 90s. The HVa worsened gradually from age 30 years to the mid-60s and more steeply beyond that age. The median amyloid PET was low until age 70 years and increased thereafter. Memory was worse in men than in women overall (P < .001) and more specifically beyond age 40 years. The HVa was lower in men than in women overall (P < .001) and more specifically beyond age 60 years. There was no sex difference in amyloid PET at any age. Within each sex, memory performance and HVa were not different by APOE ε4 status at any age. From age 70 years onward, APOE ε4 carriers had significantly greater median amyloid PET than noncarriers. However, the ages at which 10% of the population were amyloid PET positive were 57 years for APOE ε4 carriers and 64 years for noncarriers. CONCLUSIONS AND RELEVANCE: Male sex is associated with worse memory and HVa among cognitively normal individuals, while APOE ε4 is not. In contrast, APOE ε4 is associated with greater amyloid PET (from age 70 years onward), while sex is not. Worsening memory and HVa occur at earlier ages than abnormal amyloid PET. Therefore, neuropathological processes other than β-amyloidosis must underlie declines in brain structure and memory function in middle age. Our findings are consistent with a model of late-onset Alzheimer disease in which β-amyloidosis arises in later life on a background of preexisting structural and cognitive decline that is associated with aging and not with β-amyloid deposits.
Authors: William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun Journal: Alzheimers Dement Date: 2014-10-28 Impact factor: 21.566
Authors: Yvette I Sheline; John C Morris; Abraham Z Snyder; Joseph L Price; Zhizi Yan; Gina D'Angelo; Collin Liu; Sachin Dixit; Tammie Benzinger; Anne Fagan; Alison Goate; Mark A Mintun Journal: J Neurosci Date: 2010-12-15 Impact factor: 6.167
Authors: Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman Journal: N Engl J Med Date: 2009-07-16 Impact factor: 91.245
Authors: Miranka Wirth; Cindee M Madison; Gil D Rabinovici; Hwamee Oh; Susan M Landau; William J Jagust Journal: J Neurosci Date: 2013-03-27 Impact factor: 6.167
Authors: Vincent Doré; Victor L Villemagne; Pierrick Bourgeat; Jurgen Fripp; Oscar Acosta; Gael Chetélat; Luping Zhou; Ralph Martins; Kathryn A Ellis; Colin L Masters; David Ames; Oliver Salvado; Christopher C Rowe Journal: JAMA Neurol Date: 2013-07 Impact factor: 18.302
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Robert D Nebes; Beth E Snitz; Ann D Cohen; Howard J Aizenstein; Judith A Saxton; Edythe M Halligan; Chester A Mathis; Julie C Price; M Ilyas Kamboh; Lisa A Weissfeld; William E Klunk Journal: Neuropsychologia Date: 2013-08-01 Impact factor: 3.139
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen Journal: Lancet Neurol Date: 2014-09-04 Impact factor: 44.182
Authors: Andrew B Wolf; Jon Valla; Guojun Bu; Jungsu Kim; Mary Jo LaDu; Eric M Reiman; Richard J Caselli Journal: Alzheimers Res Ther Date: 2013-09-03 Impact factor: 6.982
Authors: Clifford R Jack; Heather J Wiste; David S Knopman; Prashanthi Vemuri; Michelle M Mielke; Stephen D Weigand; Matthew L Senjem; Jeffrey L Gunter; Val Lowe; Brian E Gregg; Vernon S Pankratz; Ronald C Petersen Journal: Neurology Date: 2014-04-04 Impact factor: 9.910
Authors: Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski Journal: Brain Date: 2015-07-27 Impact factor: 13.501
Authors: Brian J Lopresti; Elizabeth M Campbell; Zheming Yu; Stewart J Anderson; Ann D Cohen; Davneet S Minhas; Beth E Snitz; Sarah K Royse; Carl R Becker; Howard J Aizenstein; Chester A Mathis; Oscar L Lopez; William E Klunk; Dana L Tudorascu Journal: Neurobiol Aging Date: 2020-05-31 Impact factor: 4.673
Authors: Maria Vassilaki; Jeremiah A Aakre; Michelle M Mielke; Yonas E Geda; Walter K Kremers; Rabe E Alhurani; Mary M Machulda; David S Knopman; Ronald C Petersen; Val J Lowe; Clifford R Jack; Rosebud O Roberts Journal: Neurology Date: 2016-04-13 Impact factor: 9.910
Authors: Rachel F Buckley; Elizabeth C Mormino; Rebecca E Amariglio; Michael J Properzi; Jennifer S Rabin; Yen Ying Lim; Kathryn V Papp; Heidi I L Jacobs; Samantha Burnham; Bernard J Hanseeuw; Vincent Doré; Annette Dobson; Colin L Masters; Michael Waller; Christopher C Rowe; Paul Maruff; Michael C Donohue; Dorene M Rentz; Dylan Kirn; Trey Hedden; Jasmeer Chhatwal; Aaron P Schultz; Keith A Johnson; Victor L Villemagne; Reisa A Sperling Journal: Alzheimers Dement Date: 2018-05-24 Impact factor: 21.566
Authors: Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson Journal: Alzheimers Dement Date: 2019-05-02 Impact factor: 21.566
Authors: Jagan A Pillai; Robert S Butler; Aaron Bonner-Jackson; James B Leverenz Journal: Dement Geriatr Cogn Disord Date: 2016-09-14 Impact factor: 2.959
Authors: David S Knopman; Clifford R Jack; Emily S Lundt; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Mary M Machulda; Rosebud O Roberts; Bradley F Boeve; David T Jones; Ronald C Petersen Journal: Neurobiol Aging Date: 2016-06-16 Impact factor: 4.673